Difference between revisions of "Sorafenib (Nexavar)"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
m
m
Line 10: Line 10:
 
*[[Hepatocellular carcinoma]]
 
*[[Hepatocellular carcinoma]]
 
*[[Non-small cell lung cancer]]
 
*[[Non-small cell lung cancer]]
 +
*[[Osteosarcoma]]
 
*[[Renal cell carcinoma]]
 
*[[Renal cell carcinoma]]
 
*Soft tissue sarcoma
 
*Soft tissue sarcoma
Line 49: Line 50:
 
[[Category:Hepatocellular carcinoma medications]]
 
[[Category:Hepatocellular carcinoma medications]]
 
[[Category:Non-small cell lung cancer medications]]
 
[[Category:Non-small cell lung cancer medications]]
 +
[[Category:Osteosarcoma medications]]
 
[[Category:Renal_cell_carcinoma medications]]
 
[[Category:Renal_cell_carcinoma medications]]
 
[[Category:Desmoid tumor medications]]
 
[[Category:Desmoid tumor medications]]

Revision as of 03:38, 28 November 2021

General information

Class/mechanism: Tyrosine kinase inhibitor that inhibits multiple kinases: RAF1, BRAF, KIT, FLT-3, RET, vascular endothelial growth factor receptors VEGFR-1, VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor beta (PDGFR-B). Inhibition of these kinases disrupts angiogenesis, tumor cell signaling, and induces apoptosis.[1][2][3]
Route: PO
Extravasation: n/a

For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Also known as

  • Code names: BAY 43-9006, BAY 54-9085
  • Brand names: Nexavar, Sorafenat, Soranib

References